Literature DB >> 23667224

Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β3-adrenoceptors?

Miguel F Carrascosa1, M Isabel Lucena, Inmaculada Bellido, José Ramón Salcines-Caviedes.   

Abstract

Indacaterol is an ultra-long-acting β2-adrenoceptor agonist that is indicated for the maintenance treatment of chronic obstructive pulmonary disease. We present a patient with severe chronic constipation and abdominal pain most probably induced by this medicament. Symptoms rapidly disappeared within 2 days after the drug withdrawal. As far as we know, no reports describing severe chronic constipation associated with indacaterol have been published. The Naranjo algorithm score and the Edwards and Aronson scale for causality assessment of suspected adverse drug reactions indicated a probable relationship between indacaterol use and constipation. Indacaterol-induced constipation is an unusual event that could be accounted for the high intrinsic activity of the drug on colonic β3-adrenoreceptors, resulting in an inhibitory control of smooth muscle function and intestinal secretion. Clinicians should monitor such a possibility when prescribing this drug and maybe avoid its use in patients with a history of difficult bowel evacuation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23667224      PMCID: PMC3669958          DOI: 10.1136/bcr-2013-009568

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.

Authors:  Cliff Battram; Steven J Charlton; Bernard Cuenoud; Mark R Dowling; Robin A Fairhurst; David Farr; John R Fozard; Juliet R Leighton-Davies; Christine A Lewis; Lorraine McEvoy; Robert J Turner; Alexandre Trifilieff
Journal:  J Pharmacol Exp Ther       Date:  2006-01-24       Impact factor: 4.030

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis.

Authors:  Nicole C Suares; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2011-05-24       Impact factor: 10.864

Review 5.  Indacaterol: a novel long-acting β(2) -agonist.

Authors:  Shaunta' M Ray; James C McMillen; Sarah A Treadway; Robert S Helmer; Andrea S Franks
Journal:  Pharmacotherapy       Date:  2012-04-12       Impact factor: 4.705

6.  Colitis-induced alterations in adrenergic control of circular smooth muscle in vitro in rats.

Authors:  A Zhao; C Bossone; V Piñeiro-Carrero; T Shea-Donohue
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

Review 7.  Burden and clinical features of chronic obstructive pulmonary disease (COPD).

Authors:  Romain A Pauwels; Klaus F Rabe
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

8.  Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.

Authors:  R M Mroz; L Minarowski; E Chyczewska
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.

Authors:  Shannon Cope; Jie Zhang; James Williams; Jeroen P Jansen
Journal:  BMC Pulm Med       Date:  2012-06-25       Impact factor: 3.317

10.  Safety of indacaterol in the treatment of patients with COPD.

Authors:  James F Donohue; Dave Singh; Oliver Kornmann; David Lawrence; Cheryl Lassen; Benjamin Kramer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.